LI Xiaoying, Chief Physician, Department of Endocrinology, Zhongshan Hospital, Fudan University
14:00 - 14:30
主旨报告1
Keynote Speech 1
减重药物研发的新趋势——从数字到质量
Emerging Trends in Anti-Obesity Drug Development: From Numbers to Quality
纪立农, 北京大学人民医院内分泌科主任
JI Lilong, Director, Department of Endocrinology, Peking University People's Hospital
14:30 - 14:50
主题报告2
Thematic Report 2
长效减重制剂开发与布局策略
Development and Portfolio Strategy for Long-Acting Anti-Obesity Medications
王博, 辉瑞（北京）研究开发有限公司内科领域负责人
WANG Bo, Senior Director, Senior Category Development Lead at Pfizer China
14:50 - 15:50
主持人 Moderator
曲伸, 同济大学医学院肥胖症研究所所长，同济大学附属上海十院肥胖症管理中心主任
QU Shen, Director, Institute of Obesity, Tongji University School of Medicine; Director, Obesity and Metabolism Management Center, Shanghai Tenth People's Hospital, Tongji University
14:50 - 15:10
主题报告3
Thematic Report 3
口服减重药物设计与临床进展
Design and Clinical Advances in Oral Anti-Obesity Medications
宋文鑫, 上海民为生物技术有限公司首席科学家、副总经理
SONG Wenxin, Chief Scientist and Deputy General Manager, Shanghai Minwei Biotechnology Co., Ltd.
15:10 - 15:30
主题报告4
Thematic Report 4
减脂保肌药物的研发路径与展望
R&D Pathways and Prospects for Fat-Reducing and Muscle-Sparing Drugs
卢海, 杭州中美华东制药有限公司研发中心医学执行总监
LU Hai, Executive Medical Director, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd
15:30 - 15:50
主题报告5
Thematic Report 5
肝外递送小核酸技术在减重创新药研发中的策略和应用
Extrahepatic Delivery of Oligonucleotide Therapeutics: Strategies and Applications in Innovative Anti-Obesity Drug Development
赵孝斌, 海昶生物医药董事长、总经理
ZHAO Xiaobin, Chairman of the Board, General Manager of Haichang Biotech Co., Ltd.
15:50 - 17:10
第二阶段：主题讨论
Session II: Panel Discussions
15:50 - 16:30
主题讨论1
Panel Discussion 1
从数据兑现到健康重塑：减重药物未来价值取向
From Data Readouts to Health Transformation: The Future Value Orientation of Anti-Obesity Medications
主持人 Moderator
纪立农, 北京大学人民医院内分泌科主任
JI Lilong, Director, Department of Endocrinology, Peking University People's Hospital
讨论嘉宾： Panelist:
李小英, 复旦大学附属中山医院内分泌科主任医师
LI Xiaoying, Chief Physician, Department of Endocrinology, Zhongshan Hospital, Fudan University
Ramy Younes, 勃林格殷格翰副总裁、全球心肾代谢领域临床开发负责人
Ramy Younes, Corporate Vice President Global Head of Clinical Development CRM at Boehringer Ingelheim
李才, 罗氏中国创新中心副总裁
LI Cai, Vice President and Head of CVM Discovery and Strategy & Portfolio, China Innovation Center of Roche
会议咨询